's Chart of the Day - Abiomed
Related Stocks
 ABMD - Abiomed Inc
The Chart of the Day belongs to Abiomed (ABMD).  I found the medical instrument stock by using Barchart to sort today's New 52 Week High list first for the most frequent number of new highs in the last month, then again for technical buy signals of 80% or more. I always use the Flipchart feature to review the charts for consistent price appreciation.  Since the Trend Spotter signaled a buy on 1/5 the stock gained 31.76%.

Abiomed, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.


Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the web site when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 14 new highs and up 21.81% in the last month
  • Relative Strength Index 73.09%
  • Technical support level at 256.57
  • Recently traded at 266.21 with a 50 day moving average of 215.44

Fundamental factors:

  • Market Cap $11.56 billion
  • P/E 133.06
  • Revenue expected to grow 31.00% this year and another 27.30% next year
  • Earnings estimated to increase 97.40% this year, an additional 39.80% next year and continue to compound at an annual rate of 38.00% for the next 5 years
  • Wall Street analysts issued 5 strong buy, 3 buy and 2 hold recommendations on the stock